Editorial: Lipidomics in MASLD and MetALD—Authors' Reply

IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Kai Markus Schneider, Carolin V. Schneider
{"title":"Editorial: Lipidomics in MASLD and MetALD—Authors' Reply","authors":"Kai Markus Schneider, Carolin V. Schneider","doi":"10.1111/apt.70058","DOIUrl":null,"url":null,"abstract":"<p>We appreciate the insightful editorial [<span>1</span>] highlighting the significance of our lipidomic findings for detecting higher alcohol consumption in steatotic liver disease (SLD) [<span>2</span>]. When looking at SLD on a population level, one key challenge is that MetALD remains so rare that it is likely underreported [<span>3</span>]. This raises concerns about misclassification, particularly in cohorts relying on self-reported alcohol intake [<span>4</span>]. Biomarkers such as carbohydrate-deficient transferrin (CDT) in serum or ethylglucuronid (ETG) may serve as objective measures of alcohol intake and could be particularly useful in individuals with advanced SLD [<span>5</span>], where accurate assessment of alcohol exposure is crucial for prognosis and management. While previous studies have demonstrated the utility of CDT in detecting chronic alcohol consumption, its role in distinguishing moderate drinkers from those with excessive intake in the setting of SLD remains uncertain [<span>6</span>].</p>\n<p>HDL might be a starting point to differentiate MASLD from MetALD but, while lipidomics has provided key discriminatory markers, the next logical step is integrating proteomics to refine the distinction between these subtypes further. Beyond biochemical markers, the interaction between alcohol intake in SLD and emerging pharmacological interventions remains an area of critical importance. With the advent of novel therapies for MASLD/MASH, including Resmetirom [<span>7</span>], GLP-1 receptor agonists [<span>8</span>] and agents targeting relevant metabolic pathways, for example, FGF21 [<span>9</span>], their potential interaction with alcohol metabolism warrants further scrutiny. Additionally, the interplay between lifestyle factors, genetic risk variants and alcohol consumption remains poorly understood. Given that alcohol intake is highly variable across populations, differs over time and is influenced by socioeconomic, cultural and behavioural factors, future studies should aim to integrate multiomic data, including lipidomics, proteomics and metabolomics, to dissect these complex interactions.</p>\n<p>Moving forward, a comprehensive approach combining lipidomics, proteomics and metabolomics will be essential to uncover non-linear relationships that may remain hidden when analysing a single omics layer. We propose developing a multi-omics-based score to differentiate MASLD and MetALD more effectively, ultimately aiding in personalised risk assessment and therapeutic decisions.</p>\n<p>Lastly, lipidomic differences between MASLD and MetALD further validate the new nomenclature's attempt to differentiate subgroups within SLD [<span>10</span>]. The distinct lipid profiles observed in MetALD—particularly the elevation of HDL-centric lipidomic markers and ketone body metabolites—suggest that these two entities are biologically distinct rather than merely reflecting a continuum of alcohol exposure. This supports the concept that the classification of MetALD as a separate entity within SLD is not arbitrary but rather underpinned by measurable metabolic and lipidomic alterations.</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"4 1","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/apt.70058","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We appreciate the insightful editorial [1] highlighting the significance of our lipidomic findings for detecting higher alcohol consumption in steatotic liver disease (SLD) [2]. When looking at SLD on a population level, one key challenge is that MetALD remains so rare that it is likely underreported [3]. This raises concerns about misclassification, particularly in cohorts relying on self-reported alcohol intake [4]. Biomarkers such as carbohydrate-deficient transferrin (CDT) in serum or ethylglucuronid (ETG) may serve as objective measures of alcohol intake and could be particularly useful in individuals with advanced SLD [5], where accurate assessment of alcohol exposure is crucial for prognosis and management. While previous studies have demonstrated the utility of CDT in detecting chronic alcohol consumption, its role in distinguishing moderate drinkers from those with excessive intake in the setting of SLD remains uncertain [6].

HDL might be a starting point to differentiate MASLD from MetALD but, while lipidomics has provided key discriminatory markers, the next logical step is integrating proteomics to refine the distinction between these subtypes further. Beyond biochemical markers, the interaction between alcohol intake in SLD and emerging pharmacological interventions remains an area of critical importance. With the advent of novel therapies for MASLD/MASH, including Resmetirom [7], GLP-1 receptor agonists [8] and agents targeting relevant metabolic pathways, for example, FGF21 [9], their potential interaction with alcohol metabolism warrants further scrutiny. Additionally, the interplay between lifestyle factors, genetic risk variants and alcohol consumption remains poorly understood. Given that alcohol intake is highly variable across populations, differs over time and is influenced by socioeconomic, cultural and behavioural factors, future studies should aim to integrate multiomic data, including lipidomics, proteomics and metabolomics, to dissect these complex interactions.

Moving forward, a comprehensive approach combining lipidomics, proteomics and metabolomics will be essential to uncover non-linear relationships that may remain hidden when analysing a single omics layer. We propose developing a multi-omics-based score to differentiate MASLD and MetALD more effectively, ultimately aiding in personalised risk assessment and therapeutic decisions.

Lastly, lipidomic differences between MASLD and MetALD further validate the new nomenclature's attempt to differentiate subgroups within SLD [10]. The distinct lipid profiles observed in MetALD—particularly the elevation of HDL-centric lipidomic markers and ketone body metabolites—suggest that these two entities are biologically distinct rather than merely reflecting a continuum of alcohol exposure. This supports the concept that the classification of MetALD as a separate entity within SLD is not arbitrary but rather underpinned by measurable metabolic and lipidomic alterations.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
15.60
自引率
7.90%
发文量
527
审稿时长
3-6 weeks
期刊介绍: Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信